Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.50    2.50 (3.57%)
Bid:
71.00
Ask:
74.00
Spread: 3.00 (4.225%)
Market Cap: £329.95m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Avacta Group News

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets
1 Jun 2021

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Avacta confident despite filing delay for Covid-19 antigen test
1 Jun 2021

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 an...

Avacta still waiting on response from UK regulator over Covid test
28 May 2021

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on MHRA approval for Covid-19 test
28 May 2021

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 a...

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"
10 May 2021

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss
22 Apr 2021

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta reports positive data for Covid-19 test product
20 Apr 2021

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 a...

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial
20 Apr 2021

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial